
    
      This short-term study will assess changes in serum insulin-like growth factor 1 (IGF-1) over
      a 16-week treatment period in a patient population diagnosed with Acromegaly being treated
      with Long-acting Somatostatin Receptor Ligands (SRL)
    
  